Total Payments
$20,850
2024 Payments
$3,764
Companies
6
Transactions
31
Payment Breakdown by Category
Other$8,058 (38.6%)
Travel$7,662 (36.7%)
Research$2,764 (13.3%)
Consulting$1,750 (8.4%)
Food & Beverage$616.66 (3.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Travel and Lodging | $7,662 | 6 | 36.7% |
| Honoraria | $3,508 | 2 | 16.8% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $2,800 | 2 | 13.4% |
| Unspecified | $2,764 | 9 | 13.3% |
| Consulting Fee | $1,750 | 1 | 8.4% |
| Compensation for serving as faculty or as a speaker for a medical education program | $1,750 | 1 | 8.4% |
| Food and Beverage | $616.66 | 10 | 3.0% |
Payments by Type
General
$18,087
22 transactions
Research
$2,764
9 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Draegerwerk AG & Co. KGaA | $11,566 | 16 | $0 (2018) |
| Mallinckrodt Hospital Products Inc. | $3,500 | 2 | $0 (2022) |
| Draeger Medical Systems, Inc | $2,800 | 2 | $0 (2024) |
| Regeneron Pharmaceuticals, Inc. | $2,764 | 9 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $124.96 | 1 | $0 (2018) |
| Mallinckrodt Enterprises LLC | $95.39 | 1 | $0 (2019) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $3,764 | 10 | Regeneron Pharmaceuticals, Inc. ($2,764) |
| 2023 | $1,800 | 1 | Draeger Medical Systems, Inc ($1,800) |
| 2022 | $1,750 | 1 | Mallinckrodt Hospital Products Inc. ($1,750) |
| 2020 | $1,750 | 1 | Mallinckrodt Hospital Products Inc. ($1,750) |
| 2019 | $95.39 | 1 | Mallinckrodt Enterprises LLC ($95.39) |
| 2018 | $5,664 | 7 | Draegerwerk AG & Co. KGaA ($5,539) |
| 2017 | $6,027 | 10 | Draegerwerk AG & Co. KGaA ($6,027) |
All Payment Transactions
31 individual payment records from CMS Open Payments — Page 1 of 2
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 09/19/2024 | Draeger Medical Systems, Inc | Evita V800 (Device) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,000.00 | General |
| Category: Pulmonary/Respiratory Diseases | ||||||
| 02/16/2024 | Regeneron Pharmaceuticals, Inc. | EYLEA (Biological) | — | In-kind items and services | $988.19 | Research |
| Study: AN EXTENSION STUDY TO EVALUATE THE LONG-TERM OUTCOMES OF PATIENTS WHO RECEIVED TREATMENT FOR RETINOPATHY OF PREMATURITY IN THE VGFTE-ROP-1920 STUDY • Category: OPHTHALMOLOGY | ||||||
| 02/16/2024 | Regeneron Pharmaceuticals, Inc. | EYLEA (Biological) | — | In-kind items and services | $648.36 | Research |
| Study: AN EXTENSION STUDY TO EVALUATE THE LONG-TERM OUTCOMES OF PATIENTS WHO RECEIVED TREATMENT FOR RETINOPATHY OF PREMATURITY IN THE VGFTE-ROP-1920 STUDY • Category: OPHTHALMOLOGY | ||||||
| 02/16/2024 | Regeneron Pharmaceuticals, Inc. | EYLEA (Biological) | — | In-kind items and services | $434.27 | Research |
| Study: AN EXTENSION STUDY TO EVALUATE THE LONG-TERM OUTCOMES OF PATIENTS WHO RECEIVED TREATMENT FOR RETINOPATHY OF PREMATURITY IN THE VGFTE-ROP-1920 STUDY • Category: OPHTHALMOLOGY | ||||||
| 02/16/2024 | Regeneron Pharmaceuticals, Inc. | EYLEA (Biological) | — | In-kind items and services | $169.40 | Research |
| Study: AN EXTENSION STUDY TO EVALUATE THE LONG-TERM OUTCOMES OF PATIENTS WHO RECEIVED TREATMENT FOR RETINOPATHY OF PREMATURITY IN THE VGFTE-ROP-1920 STUDY • Category: OPHTHALMOLOGY | ||||||
| 02/16/2024 | Regeneron Pharmaceuticals, Inc. | EYLEA (Biological) | — | In-kind items and services | $150.00 | Research |
| Study: AN EXTENSION STUDY TO EVALUATE THE LONG-TERM OUTCOMES OF PATIENTS WHO RECEIVED TREATMENT FOR RETINOPATHY OF PREMATURITY IN THE VGFTE-ROP-1920 STUDY • Category: OPHTHALMOLOGY | ||||||
| 02/16/2024 | Regeneron Pharmaceuticals, Inc. | EYLEA (Biological) | — | In-kind items and services | $150.00 | Research |
| Study: AN EXTENSION STUDY TO EVALUATE THE LONG-TERM OUTCOMES OF PATIENTS WHO RECEIVED TREATMENT FOR RETINOPATHY OF PREMATURITY IN THE VGFTE-ROP-1920 STUDY • Category: OPHTHALMOLOGY | ||||||
| 02/16/2024 | Regeneron Pharmaceuticals, Inc. | EYLEA (Biological) | — | In-kind items and services | $150.00 | Research |
| Study: AN EXTENSION STUDY TO EVALUATE THE LONG-TERM OUTCOMES OF PATIENTS WHO RECEIVED TREATMENT FOR RETINOPATHY OF PREMATURITY IN THE VGFTE-ROP-1920 STUDY • Category: OPHTHALMOLOGY | ||||||
| 02/16/2024 | Regeneron Pharmaceuticals, Inc. | EYLEA (Biological) | — | In-kind items and services | $36.66 | Research |
| Study: AN EXTENSION STUDY TO EVALUATE THE LONG-TERM OUTCOMES OF PATIENTS WHO RECEIVED TREATMENT FOR RETINOPATHY OF PREMATURITY IN THE VGFTE-ROP-1920 STUDY • Category: OPHTHALMOLOGY | ||||||
| 02/16/2024 | Regeneron Pharmaceuticals, Inc. | EYLEA (Biological) | — | In-kind items and services | $36.66 | Research |
| Study: AN EXTENSION STUDY TO EVALUATE THE LONG-TERM OUTCOMES OF PATIENTS WHO RECEIVED TREATMENT FOR RETINOPATHY OF PREMATURITY IN THE VGFTE-ROP-1920 STUDY • Category: OPHTHALMOLOGY | ||||||
| 08/24/2023 | Draeger Medical Systems, Inc | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,800.00 | General |
| 06/29/2022 | Mallinckrodt Hospital Products Inc. | INOMAX (Drug) | Compensation for serving as faculty or as a speaker for a medical education program | Cash or cash equivalent | $1,750.00 | General |
| Category: CRITICAL CARE | ||||||
| 09/25/2020 | Mallinckrodt Hospital Products Inc. | INOMAX (Drug) | Consulting Fee | Cash or cash equivalent | $1,750.00 | General |
| Category: CRITICAL CARE | ||||||
| 03/28/2019 | Mallinckrodt Enterprises LLC | INOMAX (Drug) | Food and Beverage | In-kind items and services | $95.39 | General |
| Category: CRITICAL CARE | ||||||
| 11/15/2018 | Draegerwerk AG & Co. KGaA | BABYLOG VN500 (Device) | Travel and Lodging | Cash or cash equivalent | $2,965.97 | General |
| Category: Ventilation | ||||||
| 10/23/2018 | Draegerwerk AG & Co. KGaA | BABYLOG VN500 (Device) | Travel and Lodging | In-kind items and services | $378.33 | General |
| Category: Ventilation | ||||||
| 10/11/2018 | Draegerwerk AG & Co. KGaA | BABYLOG VN500 (Device) | Travel and Lodging | In-kind items and services | $369.04 | General |
| Category: Ventilation | ||||||
| 10/04/2018 | Draegerwerk AG & Co. KGaA | BABYLOG VN500 (Device) | Food and Beverage | In-kind items and services | $45.33 | General |
| Category: Ventilation | ||||||
| 10/04/2018 | Draegerwerk AG & Co. KGaA | BABYLOG VN500 (Device) | Food and Beverage | In-kind items and services | $40.97 | General |
| Category: Ventilation | ||||||
| 08/29/2018 | AstraZeneca Pharmaceuticals LP | SYNAGIS (Biological) | Food and Beverage | In-kind items and services | $124.96 | General |
| Category: Respiratory | ||||||
| 06/18/2018 | Draegerwerk AG & Co. KGaA | BABYLOG VN500 (Device) | Honoraria | Cash or cash equivalent | $1,739.04 | General |
| Category: Ventilation | ||||||
| 11/15/2017 | Draegerwerk AG & Co. KGaA | BABYLOG VN500 (Device) | Honoraria | Cash or cash equivalent | $1,768.84 | General |
| Category: Ventilation | ||||||
| 10/25/2017 | Draegerwerk AG & Co. KGaA | BABYLOG VN500 (Device) | Travel and Lodging | Cash or cash equivalent | $3,238.39 | General |
| Category: Ventilation | ||||||
| 10/25/2017 | Draegerwerk AG & Co. KGaA | BABYLOG VN500 (Device) | Travel and Lodging | In-kind items and services | $399.80 | General |
| Category: Ventilation | ||||||
| 10/25/2017 | Draegerwerk AG & Co. KGaA | BABYLOG VN500 (Device) | Travel and Lodging | In-kind items and services | $310.43 | General |
| Category: Ventilation | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| AN EXTENSION STUDY TO EVALUATE THE LONG-TERM OUTCOMES OF PATIENTS WHO RECEIVED TREATMENT FOR RETINOPATHY OF PREMATURITY IN THE VGFTE-ROP-1920 STUDY | Regeneron Pharmaceuticals, Inc. | $2,764 | 9 |
About Dr. Martin Keszler, M.D
Dr. Martin Keszler, M.D is a Neonatal-Perinatal Medicine healthcare provider based in Providence, Rhode Island. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/20/2005. The National Provider Identifier (NPI) number assigned to this provider is 1083613244.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Martin Keszler, M.D has received a total of $20,850 in payments from pharmaceutical and medical device companies, with $3,764 received in 2024. These payments were reported across 31 transactions from 6 companies. The most common payment nature is "Travel and Lodging" ($7,662).
Ad
Practice Information
- Specialty Neonatal-Perinatal Medicine
- Location Providence, RI
- Active Since 07/20/2005
- Last Updated 08/15/2024
- Taxonomy Code 2080N0001X
- Entity Type Individual
- NPI Number 1083613244
Products in Payments
- BABYLOG VN500 (Device) $11,566
- INOMAX (Drug) $3,595
- EYLEA (Biological) $2,764
- Evita V800 (Device) $1,000
- SYNAGIS (Biological) $124.96
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Neonatal-Perinatal Medicine Doctors in Providence
Yun Lee, Md, MD
Neonatal-Perinatal Medicine — Payments: $107.76
Neonatal-Perinatal Medicine $107.76
Edward Hurley, M.d, M.D
Neonatal-Perinatal Medicine — Payments: $83.09
Neonatal-Perinatal Medicine $83.09
Semsa Gogcu, M.d, M.D
Neonatal-Perinatal Medicine — Payments: $75.23
Neonatal-Perinatal Medicine $75.23
Dr. Ross Sommers, M.d, M.D
Neonatal-Perinatal Medicine — Payments: $62.21
Neonatal-Perinatal Medicine $62.21
Abbot Laptook, Md, MD
Neonatal-Perinatal Medicine — Payments: $60.98
Neonatal-Perinatal Medicine $60.98
Mrs. Barbara Stonestreet, M.d, M.D
Neonatal-Perinatal Medicine
Neonatal-Perinatal Medicine